Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

1.7K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PARP7 inhibitors enhance the immunogenic effects of radiation in pancreatic cancer cells.

Molecular therapy. Oncology·2026
Same author

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis.

International journal of cancer·2025
Same author

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism.

Molecular oncology·2025
Same author

The janus-faced effect of PD1 signaling on bone: do sex and age matter?

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

Real-world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysis.

Oncology letters·2025
Same author

Palliative Radiotherapy Near the End of Life: An Analysis of Factors Influencing the Administration of Radiotherapy in Advanced Tumor Disease.

JCO global oncology·2025

Related Experiment Video

Updated: Feb 23, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Adoptive cell therapy in multiple Myeloma.

Sonia Vallet1, Martin Pecherstorfer1, Klaus Podar1

  • 1a Department of Internal Medicine , Karl Landsteiner University of Health Sciences, University Hospital , Krems an der Donau , Austria.

Expert Opinion on Biological Therapy
|September 1, 2017
PubMed
Summary
This summary is machine-generated.

Adoptive cell therapy (ACT) shows promise for multiple myeloma (MM) treatment, offering potential long-term disease control. This immunotherapy approach, including CAR T cells, may revolutionize MM therapy despite existing challenges.

Keywords:
Multiple myelomaTCR- engineered T cellsadoptive cell therapyantigen presenting cells (APC)chimeric antigen receptor (CAR) cellsdendritic cells (DCs)marrow infiltrating lymphocytes (MILs)tumor associated antigens (TAAs)

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K

Related Experiment Videos

Last Updated: Feb 23, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K

Area of Science:

  • Immunotherapy
  • Hematology
  • Oncology

Background:

  • Multiple Myeloma (MM) treatment has advanced with monoclonal antibodies.
  • Adoptive cell therapy (ACT) is a powerful immunotherapy modality for MM.
  • ACT involves ex vivo expansion and re-infusion of effector cells.

Purpose of the Study:

  • To review current knowledge on ACT in MM.
  • To discuss the promises and challenges of ACT for MM.
  • To outline future strategies for ACT in MM treatment paradigms.

Main Methods:

  • Review of existing literature on ACT in MM.
  • Analysis of clinical studies involving CAR T cells and TCR-engineered T cells.
  • Discussion of naturally occurring and genetically-engineered effector cells for ACT.

Main Results:

  • Early clinical studies of CAR T cells and TCR-engineered T cells in relapsed/refractory MM are promising.
  • These ACT approaches indicate potential for long-term disease control or cure.
  • Monoclonal antibodies like elotuzumab and daratumumab represent recent immunotherapy breakthroughs.

Conclusions:

  • ACT, particularly CAR T and TCR-engineered T cells, holds significant potential to revolutionize MM therapy.
  • Overcoming toxicity, cost, and availability are key challenges for ACT integration.
  • ACT strategies are crucial for future MM treatment paradigms.